Diasorin SpAWBO:DIAS +0.09%74 10-Year ROIIC % is 4.09 as of Dec. 2025. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €89.88 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 179 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 55.87% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Diasorin SpA's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 4.09%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Diasorin SpA's 10-Year ROIIC % or its related term are showing as below:
WBO:DIAS's 10-Year ROIIC % is ranked better than 55.87% of 179
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.55
vs WBO:DIAS: 4.09
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Diasorin SpA 10-Year ROIIC % Related Terms
Diasorin SpA 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:DIAS vs TMO, DHR, IDXX: 10-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA 10-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's 10-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Diasorin SpA (WBO:DIAS) has a 10-Year ROIIC % of 4.09 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Diasorin SpA and its competitors. According to the industry distribution chart, Diasorin SpA ranks #79 out of 179 companies in the Medical Diagnostics & Research industry, placing it in the top 44.1%.
Is Diasorin SpA's 10-Year ROIIC % too high?
Diasorin SpA's current 10-Year ROIIC % is 4.09. The Medical Diagnostics & Research industry median 10-Year ROIIC % is 1.55. Diasorin SpA's value of 4.09 is 163.9% above this industry median. Based on the distribution chart, Diasorin SpA ranks #79 out of 179 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's 10-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #79 out of 179 companies for 10-Year ROIIC %. This puts Diasorin SpA in the upper half of its industry. The industry median 10-Year ROIIC % is 1.55. Diasorin SpA's value of 4.09 is 163.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Medical Diagnostics & Research company?
The median 10-Year ROIIC % among Medical Diagnostics & Research companies is 1.55, based on 179 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current 10-Year ROIIC % of 4.09 is 163.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median 10-Year ROIIC % is 1.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current 10-Year ROIIC % is 4.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €89.88, compared to a current price of €69.78 — trading 22.4% below its estimated fair value. The current 10-Year ROIIC % is 4.09 and 163.9% above the Medical Diagnostics & Research industry median of 1.55. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current 10-Year ROIIC % is 4.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €69.78 is trading 22.4% below its estimated GF Value™ of €89.88.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for WBO:DIAS:
10-Year ROIIC %: 4.09
GF Value™: €89.88 vs. price of €69.78 (22.4% below fair value)
Industry Position: 163.9% above the Medical Diagnostics & Research median (#79 of 179)
No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score
Get the complete analysis for WBO:DIAS
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:DIAS has been successfully added to your 
